ND: |
ME11338782 |
PMID: |
11338782 |
LR: |
20061115 |
CED: |
20010507 |
DCO: |
20010521 |
Autoren: |
Reginster JY; Henrotin Y |
Titel: |
Pharma clinics. Comment je traite.... L'arthrose. 2ème partie: nouvelles perspectives thérapeutiques. Pharmacy clinics. How I treat...Osteoarthritis. 2nd part: new therapeutic perspectives |
Quelle: |
Revue médicale de Liège; VOL: 56 (3); p. 135-9 /200103/ |
PM: |
Print |
SU: |
IM |
Sprache: |
French |
CY: |
Belgium |
JID: |
0404317 |
ISSN: |
0370-629X |
CO: |
RMLIAC |
Institution: |
Service de Santé Publique et d'Epidémiologie, Centre Collaborateur Organisation Mondiale de la Santé pour les Aspects de Santé Publique des Maladies Rhumatismales, Liège. |
DT: |
English Abstract; Journal Article |
Schlagwörter |
CT: |
ANTHRAQUINONES/pharmacology; ANTHRAQUINONES/therapeutic use; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/pharmacology; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/therapeutic use; CHONDROITIN/pharmacology; CHONDROITIN/*therapeutic use; DISEASE PROGRESSION; GLUCOSAMINE/pharmacology; GLUCOSAMINE/*therapeutic use; HUMANS; HYALURONIC ACID/pharmacology; HYALURONIC ACID/*therapeutic use; OSTEOARTHRITIS/*drug therapy |
CTG: |
ANTHRACHINONE/Pharmakologie; ANTHRACHINONE/therapeutische Anwendung; ANTIPHLOGISTIKA, NICHTSTEROIDALE/Pharmakologie; ANTIPHLOGISTIKA, NICHTSTEROIDALE/therapeutische Anwendung; CHONDROITIN/Pharmakologie; CHONDROITIN/*therapeutische Anwendung; KRANKHEITSPROGRESSION; GLUCOSAMIN/Pharmakologie; GLUCOSAMIN/*therapeutische Anwendung; MENSCH; HYALURONSÄURE/Pharmakologie; HYALURONSÄURE/*therapeutische Anwendung; OSTEOARTHROSE/*Arzneimitteltherapie |
TE: |
Anthraquinones; Anti-Inflammatory Agents, Non-Steroidal; diacetylrhein/13739-02-1; Glucosamine/3416-24-8; Hyaluronic Acid/9004-61-9; Chondroitin/9007-27-6 |
CR: |
13739-02-1; 3416-24-8; 9004-61-9; 9007-27-6 |
AB: |
Besides the management of symptoms of osteoarthritis, a lot of interest was raised for molecules aiming at slowing down the structural progression of the disease. This paper summarizes the currently available data allowing to discuss the efficacy and tolerance of these chemical entities. |